<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124560">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02143973</url>
  </required_header>
  <id_info>
    <org_study_id>TR02ext</org_study_id>
    <secondary_id>2013-005625-22</secondary_id>
    <nct_id>NCT02143973</nct_id>
  </id_info>
  <brief_title>Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus</brief_title>
  <official_title>An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trevi Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trevi Therapeutics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER
      tablets during a treatment period of up to 24 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>A description of the overall incidence frequency and nature of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>A description of the incidence frequency and nature of Treatment Emergent Adverse Events (TEAEs) during Treatment by achieved dose</measure>
    <time_frame>Week 3, Week 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Uremic Pruritus</condition>
  <condition>Pruritus</condition>
  <arm_group>
    <arm_group_label>nalbuphine HCl ER 60mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nalbuphine HCl ER 60mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nalbuphine HCl ER 90mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nalbuphine HCl ER 90mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nalbuphine HCl ER 120mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nalbuphine HCl ER 120mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nalbuphine HCl ER 60mg BID</intervention_name>
    <description>nalbuphine HCl ER 60mg BID for up to 24 weeks</description>
    <arm_group_label>nalbuphine HCl ER 60mg</arm_group_label>
    <other_name>nalbuphine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nalbuphine HCl ER 90mg BID</intervention_name>
    <description>nalbuphine HCl ER 90mg BID for up to 24 weeks</description>
    <arm_group_label>nalbuphine HCl ER 90mg</arm_group_label>
    <other_name>nalbuphine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nalbuphine HCl ER 120mg BID</intervention_name>
    <description>nalbuphine HCl ER 120mg BID for up to 24 weeks</description>
    <arm_group_label>nalbuphine HCl ER 120mg</arm_group_label>
    <other_name>nalbuphine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject completed participation in the TR02 study

          -  Subject is currently receiving in-center hemodialysis at the time of consent

        Exclusion Criteria:

          -  Subject receiving or anticipated to be receiving nocturnal dialysis or home
             hemodialysis treatment during the study

          -  Subject received opiates on a daily basis during the 1 week  prior to screening

          -  Other than the TR02 Study Drug, Subject received any investigational drug within 4
             weeks prior to Screening

          -  Subject is a pregnant or lactating female
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Sciascia, MD</last_name>
    <role>Study Director</role>
    <affiliation>Trevi Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roberta Duncan</last_name>
    <phone>203-304-2499</phone>
    <email>roberta.duncan@trevitherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Sciascia, MD</last_name>
    <phone>203-304-2499</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baystate Health</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>May 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uremic</keyword>
  <keyword>Pruritus</keyword>
  <keyword>Itch</keyword>
  <keyword>Chronic Itch</keyword>
  <keyword>Nalbuphine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nalbuphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
